登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 10 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 10
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心南通大学附属医院Affiliated Hospital of Nantong University南通医院页面
- 研究中心佛山市第一人民医院First People's Hospital of Foshan佛山医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
- 研究中心北京大学深圳医院Peking University Shenzhen Hospital深圳医院页面
- 研究中心深圳市人民医院Shenzhen People's Hospital深圳医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06709274,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas.
入选标准第 1 条
Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition).
入选标准第 2 条
Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision.
入选标准第 4 条
Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.
排除标准第 6 条
Blood transfusion within 2 weeks prior to and during the surgery.
排除标准第 20 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
入选标准第 5 条
Absolute neutrophil count ≥1.5×10\^9/L
入选标准第 8 条
Platelet count ≥100×10\^9/L
入选标准第 9 条
Hemoglobin ≥90 g/L
入选标准第 10 条
ALT ≤2.5× upper limit of normal (ULN)
入选标准第 11 条
AST ≤2.5×ULN
入选标准第 12 条
Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula).
入选标准第 13 条
History of other malignancies within the past 5 years, with the exception of the following:
排除标准第 7 条
Other malignancies fully cured by surgery with a disease-free survival of more than 10 years
排除标准第 8 条
Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion.
入选标准第 16 条
Pregnant or breastfeeding females.
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06709274,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas. Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition). Completely surgical resection (R0) of the primary NSCLC via lobectomy, segmentectomy, or sleeve lobectomy. The gross tumor must be entirely removed, and all surgical margins of the excised tumor must be negative. Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. Minimum life expectancy of ≥12 weeks. Demonstrate adequate organ function, including: Absolute neutrophil count ≥1.5×10\^9/L Platelet count ≥100×10\^9/L Hemoglobin ≥90 g/L ALT ≤2.5× upper limit of normal (ULN) AST ≤2.5×ULN Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula). Male or female, age between 18 and 75 years. Written informed consent must be obtained from the subject or their legal representative. Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion. Willingness and ability to comply with visit schedules, treatment plans, and laboratory assessments.排除标准:Exclusion Criteria:
Histopathologically confirmed small cell carcinoma components. Presence of multiple pulmonary nodules. Incomplete resections (R1/R2) or resections via bilateral lobectomy, pneumonectomy, or wedge resection. A history of any systemic anti-tumor treatment, including but not limited to surgery, neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy. Significant allergies to any targeted drugs, immunotherapies, or chemotherapy agents used in the study. Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery. History of other malignancies within the past 5 years, with the exception of the following: Other malignancies fully cured by surgery with a disease-free survival of more than 10 years Curable basal cell carcinoma of the skin Bladder carcinoma in situ Cervical carcinoma in situ History of interstitial lung disease, drug-induced interstitial lung disease, radiation-induced pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease. Active hepatitis B, defined as HBsAg positive with an HBV-DNA copy number exceeding the ULN established by the study center, accompanied by abnormal liver function, or requiring treatment as evaluated by the investigator. Presence of any unstable systemic disease, including but not limited to active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past 3 months, serious arrhythmias that requires medication, liver disease, kidney disease, or metabolic disorders. Evidence of any other diseases, neurological or metabolic disorders, or physical exam or laboratory findings that may suggest contraindications for the investigational drug, or a high risk for treatment-related complications. Any of the following cardiac conditions: Resting ECG QT interval (QTc) > 470 msec. Significant abnormalities in rhythm, conduction, or morphology on resting ECG, including complete left bundle branch block, third-degree atrioventricular block, or second-degree atrioventricular block Factors increasing the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under the age of 40, or use of medications known to prolong QT interval. Blood transfusion within 2 weeks prior to and during the surgery. History of alcohol or drug abuse. Pregnant or breastfeeding females. Any other factors that the investigator deems may affect the progress of the study or compromise the trial data
引自 ClinicalTrials.gov, NCT06709274, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06709274,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。